This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

DiaDexus, Inc. Appoints Ralf Schoenbrunner To Senior Vice President, Research And Early Development

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that E. Ralf Schoenbrunner, Ph.D. has been appointed to the position of senior vice president of research and early development. Dr. Schoenbrunner has more than 20 years of experience in the medical device and diagnostic field including executing multiple successful product development projects.

“Dr. Schoenbrunner has a proven track record of increasing innovation and productivity within diagnostic companies by planning and directing all aspects of the organization’s research and development initiatives,” said Brian Ward, Ph.D., diaDexus’ president and chief executive officer. “He will play a critical role on our team as we identify and develop our product pipeline opportunities.”

Most recently, Dr. Schoenbrunner was the vice president of research and development, molecular diagnostics for Life Technologies Corporation, a global biotechnology tools company where he helped to build R&D capabilities for IVD diagnostics. Dr. Schoenbrunner came to Life Technologies Corporation in 2010 as a key employee through the acquisition of AcroMetrix where he was the vice president of research and development. During his tenure at AcroMetrix, a privately held company and world market leader for nucleic acid testing quality and control materials, the company launched 30 new products. From 1992 to 2006, Dr. Schoenbrunner held various positions in the research department at Roche Diagnostics in Switzerland and Roche Molecular Systems Inc. in California, both world market leaders in diagnostics. Dr. Schoenbrunner was amongst others responsible for the development of a fully automated anti-HIV-1/2 assay and development of the first COBAS TaqMan HIV-1 Test. He studied at University of Regensburg where he got his Master of Science and also at the University of Edinburgh. He received his Ph.D. in Physical Biochemistry from the University of Bayreuth in Germany.

“It’s an exciting time to join the diaDexus team as they execute on the goal of creating a robust product pipeline,” Dr. Schoenbrunner said. “I look forward to being an active part of the team that identifies, develops and commercializes new cardiovascular products.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs